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SuperoxideElectron transfer ﬂavoprotein:ubiqionone oxidoreductase (ETF-QO) is a component of the mitochondrial
respiratory chain that together with electron transfer ﬂavoprotein (ETF) forms a short pathway that transfers
electrons from 11 different mitochondrial ﬂavoprotein dehydrogenases to the ubiquinone pool. The X-ray
structure of the pig liver enzyme has been solved in the presence and absence of a bound ubiquinone. This
structure reveals ETF-QO to be a monotopic membrane protein with the cofactors, FAD and a [4Fe–4S]+1+2
cluster, organised to suggests that it is the ﬂavin that serves as the immediate reductant of ubiquinone. ETF-
QO is very highly conserved in evolution and the recombinant enzyme from the bacterium Rhodobacter
sphaeroides has allowed the mutational analysis of a number of residues that the structure suggested are
involved in modulating the reduction potential of the cofactors. These experiments, together with the
spectroscopic measurement of the distances between the cofactors in solution have conﬁrmed the
intramolecular pathway of electron transfer from ETF to ubiquinone. This approach can be extended as the
R. sphaeroides ETF-QO provides a template for investigating the mechanistic consequences of single amino
acid substitutions of conserved residues that are associated with a mild and late onset variant of the metabolic
disease multiple acyl-CoA dehydrogenase deﬁciency (MADD).ugh).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial β-oxidation of long-chain fatty acids is important in
meeting the energy requirements of heart and skeletal muscle [1].
During the β-oxidation process the two carbon units are removed
from long-chain acyl-CoA esters by repeated cycles of oxidation,
hydration, oxidation and thiolysis. In each cycle the initial oxidation
step is catalysed by one of four chain-length speciﬁc FAD-containing
dehydrogenases [2–4]. The identiﬁcation of the ﬁrst three of these
acyl-CoA dehydrogenases in the 1950s was followed by the
identiﬁcation of the electron transfer ﬂavoprotein (ETF) as their
common electron acceptor [5]. A further 20 years elapsed before ETF:
ubiquinone oxidoreductase was puriﬁed from beef heart mitochon-
dria by Ruzicka and Beinert and shown to mediate electron transfer
between ETF and ubiquinone [6]. It is now recognised that the ETF/
ETF:QO system serves as a short electron transfer pathway (Fig. 1) to
conduct electrons from nine different mitochondrial FAD-containing
acyl-CoA dehydrogenases of fatty acid β-oxidation and amino acid
catabolism to the ubiquinone pool of the main respiratory chain
[7,8]. The same pathway also accepts electrons from sarcosine
dehydrogenase and dimethylglycine dehydrogenase, two enzymes
of mitochondrial one-carbon metabolism [9]. The ubiquinone pool
in the inner mitochondrial membrane accessed by ETF:QO is alsothat accessed by NADH derived from carbohydrate and ketone body
(β-hydroxybutyrate) oxidation via complex I of the main respiratory
chain [10]. This potential for cross-talk may provide the basis for the
regulation of fatty acid oxidization by the cytosolic [NAD+]/[NADH]
ratio [11,12].
ETF:QO puriﬁed from pig liver submitochondrial particles is a single
subunit membrane protein of Mr ~64 kDa that contains FAD Fe and S in
a 1:4:4 ratio [13]. These properties, alongwith the UV/vis spectrum and
EPR spectrum of the enzyme after complete reduction with dithionite,
are very similar to those of the beef heart enzyme [6]. The EPR spectrum
of the fully (3-electron) reduced enzyme together with resonance
Raman data and low-temperature magnetic CD spectroscopy are
consistent with the presence of a single [4Fe–4S]+1+2 cluster that is
diamagnetic in the ground state [14,15]. The reduction potentials of the
FAD and [4Fe–4S]+1+2 prosthetic groups in the pig liver enzyme were
determined by EPR-spectroelectrochemical titrations. These measure-
ments yielded potentials of +28 mV for the ﬁrst and −6 mV for the
second electron transfer to the ﬂavin, and a potential of+47 mV for the
[4Fe–4S]+1+2cluster at pH 7.4 [16]. Since the reduction potentials of
the [4Fe–4S]+2/[4Fe–4S]+1 and FADox/FAD1e− couples are similar a
single electron will rapidly equilibrate between the two centres. In the
two-electron reduced enzyme both centres will contain one electron
and only when fully (3-electron) reduced will the ﬂavin will exist as
the hydroquinone.
ETF:QO is usually assayed spectrophotometrically in a coupled
reaction with octanoyl-CoA as the electron donor and ubiquinone-1
or -2 (Q1 or Q2) as the electron acceptor; the reaction is coupled in
Fig. 1. Electron-transfer fromOctanoyl-CoA to Ubiquinone is mediated by ETF and ETF-QO Octanoyl-CoA is oxidized to oct-2-3-enoyl-CoA bymedium-chain acyl-CoA dehydrogenase
(MCAD). The two electron reduced ﬂavin cofactor (FADH2) of MCAD is re-oxidized by two equivalents of electron-transfer ﬂavoprotein which is a one electron carrier. The ETF ﬂavin
semiquinone is in turn reoxidized by ETF-QO which catalyses the transfer of the electrons to the mitochondrial ubiquinone pool. The ETF/ETF-QO system serves as the electron
acceptor for nine mitochondrial ﬂavoprotein dehydrogenases: short-chain acyl-CoA dehydrogenase (EC 1.3.99.2); medium-chain acyl-CoA dehydrogenase (EC 1.3.99.3); long-chain
acyl-CoA dehydrogenase (EC 1.3.99.13); very long-chain acyl-CoA dehydrogenase; ACAD-9; isovaleryl-CoA dehydrogenase (EC 1.3.99.10); 2-methyl-butyryl-CoA dehydrogenase;
Isobutyryl-CoA dehydrogenase and glutaryl-CoA dehydrogenase (EC 1.3.99.7). The same pathway is also responsible for accepting electrons from sarcosine dehydrogenase
(EC 1.5.99.1) and dimethylglycine dehydrogenase (EC 1.5.99.2). Figure drawn with Pymol (v0.99 using the following pdb ﬁles 3MDD (MCAD), 1EFV (ETF) and 2GMH (ETF-QO).
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dehydrogenase and ETF, Eq. (1) [17,18]. The enzyme can also be
assayed spectrophotometrically by its capacity to disproportionate
ETF semiquinone (ETF1e−), Eq. (2) [17,19], a reaction that requires
only a functional iron–sulfur cluster [20,21].
Octanoyl‐CoAþ Q1←→Q1H2 þ Oct‐2‐enoyl‐CoA ð1Þ
2ETF1←→ETFox þ ETF2 ð2Þ2. The structure of ETF:QO and its quinone binding site
The X-ray structure of ETF:QO (64 kDa) puriﬁed from pig liver
mitochondria has been solved 2.1 Ǻ resolution in the presence and
absence of bound ubiquinone [22]. The 33 amino acid leader sequence
that is required to target the nuclear encoded protein to the inner
mitochondrial membrane is removed proteolytically from the ETF:QO
precursor as the protein is translocated intomitochondria. Themature
protein, despite behaving like an integral membrane protein, has no
membrane-spanning helices.
ETF:QO contain three functional domains which are closely packed
and also share some structural elements. The protein has no isolated
structural domains, but has three clear functional domains that bind
the FAD, iron–sulfur cluster and ubiquinone redox centers [21]. The
FAD containing domain and the ubiquinone binding domain are
intertwined whilst the iron–sulfur cluster domain is located at the
carboxyl terminal region and comprises ca 140 amino acids (Fig. 2A).
The isoalloxazine ring of the ﬂavin is buried 13 Å below the protein
surface and is 8.5 Å distant from the cluster which is also buried. The
iron–sulfur cluster and bound ubiquinone are separated by 19 Å, a
distance that exceeds the generally accepted limit of 14 Å for
biological electron transfer [23], making it unlikely that the cluster
is the immediate reductant of ubiquinone (Fig. 1B). However, since
the cluster is close to the surface of the protein, it seemed likely that
this would be the site for electron transfer from ETF and more recent
work with the ETF-QO from Rhodobacter sphaeroides shows this to be
the case (see below).
Watmough et al. [18] initially showed that porcine ETF-QO
contained a single ubiquinone binding site which has a Kd for a
synthetic brominated ubiquinone analog, 2 μM, that is similar to the
kinetic Km (Table 1). The presence of this ubiquinone-binding site was
conﬁrmed by the X-ray structure in which ﬁve of the 10 isoprenegroups of the ubiquinone side chain are visible [22] (Fig. 3). Two
hydrophobic regions, an α-helix (Gly427–Trp451) and a strand-loop-
strand motif (Phe114–Leu131), located at the base of the molecule,
form a channel to the binding pocket for the 1,4-benzoquinone ring
of ubiquinone (Fig. 3A). The tryptophan at position 443 is conserved
in the ETF:QO from R. sphaeroides and is a good candidate for the
residue whose intrinsic ﬂuorescence is speciﬁcally quenched by
binding of 6-(10-bromodecyl)ubiquinone to both pig [18] and
Rhodobacter enzymes [FEF unpublished data].
The head of the binding pocket which is adjacent to the 4-carbonyl
oxygen atom of the benzoquinone ring is delineated by a highly
conserved sequence Thr270-His278 (Figs. 3B and 4). Although the
tyrosine residue at position 271 is located close to the quinone ring
the extent of π–π overlap is minimal. However, this residue is in
hydrogen bonding distance of an ordered water molecule (WAT 757),
which in turn is within hydrogen bonding distance of the 4-carbonyl
group of the benzoquinone ring. The 4-carbonyl group of the
benzoquinone ring is also within hydrogen bonding distance of
the main chain atoms of Gly272 and Gly273. There is no obvious
ligand to the 1-carbonyl group and the signiﬁcance of the H-bonding
network around the 4-carbonyl group for the mechanism of
ubiquinone reduction is unclear as the Tyr271 is not conserved in
the R. sphaeroides enzyme discussed below (Fig. 4).
The axis of the α-helix (Gly427–Trp451) runs parallel to mem-
brane surface and together with the β-hairpin (Phe114–Leu131)
forms a hydrophobic plateau [22] similar to that found in a number of
other monotopic proteins like the prostaglandin synthases, squalene
cyclase, glycerol phosphate dehydrogenase (another mitochondrial
ubiquinone oxidoreductase) and fatty acid amide hydrolase [24–27].
In common with ETF:QO each of these enzymes has a lipid substrate
that must enter the active site from the membrane phase. The
hydrophobic plateau in ETF-QO is surrounded by a number of basic
residues which are presumed to interact with the phospholipid head
groups of the inner mitochondrial membrane and suggest that the
penetration of the benzoquinone head group into the molecule is in
the order of 8 Ǻ [22].
The primary amino acid sequence of the single polypeptide of
ETF:QO is highly conserved across the Kingdoms of Life (Fig. 4).
Consequently the high resolution X-ray structure of the pig liver
enzyme provides a framework for understanding the biophysical and
kinetic properties of ETF:QO from anumber ofmodel organisms. Given
the importance of ETF:QO in normal and disordered intermediary
metabolism (see below) it would be useful to have a reliable source
Fig. 2. The Structure of ETF:QO (A) The domain organisation of an ETF-QOmonomer relative to the inner mitochondrial. The overall fold of the protein is represented as ribbons with
the FAD binding domain shown in cyan, the ubiquinone binding domain in green and the cluster binding domain in red. The cofactors are represented as sticks; FAD (yellow),
ubiquinone (blue) and 4Fe–4S cluster (brown). (B) Shortest distances between the redox active cofactors of ETF-QO as determined from the crystal structure. (C) The potentials of
physiologically signiﬁcant redox couples in pig liver ETF-QO, data from Paulson et al. [16]. The ﬁgure was prepared using PyMol v0_99rc6 and the coordinates from PDB ﬁle 2GMH.
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in particular to understand the mechanistic basis of some clinically
relevant mutations. However attempts to express human ETF-QO in
both yeast [28] and baculovirus [29] met with mixed success and
prompted a search for a species that has a homologous enzyme that
can be expressed at high yield.
One such organism is R. sphaeroides, a Gram-negative photosyn-
thetic bacterium, which contains an aerobic respiratory chain
remarkably similar to that of the mitochondrion. R. sphaeroides
respiratory enzymes including the cytochrome bc1 complex and
cytochrome c oxidase have proven useful for mechanistic studies
[30,31] and for modelling single amino acid mutations that are
associated with human disease [32]. The ETF-QO from R. sphaeroides,
which can be expressed at high yield in Escherichia coli [20,21], has
67% sequence identity with the mature human protein (Fig. 4) and
is therefore an excellent template for the ab initio design and testing
of variants that contain amino acid substitutions which inﬂuence
catalytic activity [20,21].
3. Cofactor distances in measured in solution
The distances between the reduced iron–sulfur cluster ([4Fe–4S]+1)
and the ﬂavin semiquinone for the human, porcine and Rhodobacter
enzymes have been measured in solution using EPR spectroscopy [33].
In each case two-electron reduced ETF-QO was prepared by anaerobic
titration with octanoyl-CoA in the presence of medium chain acyl-
CoA dehydrogenase and ETF and the relative populations of theTable 1
Kinetic constants for quinone reduction by ETF:QO.a
Substrate Km (μM) kcat (s−1) kcat/Km (s−1/μM)
6-nonylubiquinone 1.6 246 147
6-(10-hydroxydecyl)ubiquinone 1.8 132 73.3
6-heptylubiquinone 2.0 182 89.7
Ubiquinone 2 2.3 162 70.4
6-(10-bromodecyl)ubiquinone 2.6 210 80.8
Ubiquinone 1 4.5 84 18.7
a Data from Watmough et al. [18].paramagnetic centers together with their g-values, linewidths and
relaxation rates were determined to characterize the ETF-QOs.
Differences in g-values and electron spin relaxation rates show that
the environment of the cofactors in the R. sphaeroides enzyme differs
only slightly from the porcine protein. The inter-spin distance, i.e. from
ﬂavin semiquinone to reduced cluster, was determined by analyzing
the effect of the paramagnetic [4Fe–4S]+1 cluster on the spin-lattice
relaxation rates of the anionic semiquinone and on the relative
intensities of two-pulse spin echoes as a function of temperature [33].
The average point-dipole distances between the iron–sulfur cluster and
the semiquinone in mammalian or bacterial ETF-QOs are 18.6±1.0 Å.
Two corrections to the point dipole distance are required to allow
comparison with the X-ray structure. The 8α-methyl group of the
isoalloxazine ring is about 4.5 Å from the centre of spin density on
the ﬂavin semiquinone and an individual iron atom is 1.7 Å from the
centre of the tetrahedron of the iron–sulfur cluster. Subtraction of
6.2 Å from the average point dipole distance of 18.6 Å gives an
estimated distance of 12.4±1 Å which is within error for the
ﬂavin→cluster distance of 11.5 Å determined by X-ray crystallogra-
phy. Moreover this distance does not change in any of the variant
forms of the R. sphaeroides protein that we have expressed [20,21].
The structural, oxidation–reduction potentials and ability to use
human ETF as an electron donor (see below) support the use of the
R. sphaeroides ETF-QO as a model to understand structure–function
relationships of the human protein.
4. Internal electron transfer and the role of the quinone
The intramolecular electron transfer pathway through ETF-QO has
been mapped by introducing point mutations into the R. sphaeroides
enzyme that eliminate the hydrogen bonds that are responsible for
modulating the reduction potential of either the ﬂavin [20,21] or the
iron–sulfur cluster [20,21]. The rationale was that if the reduction
potential of one of redox centres was reduced sufﬁciently it would
become physiologically inactive whilst retaining the structural
integrity of the enzyme. None of the mutations altered the structure
of the protein as judged by three criteria; the absorption spectrum, the
EPR spectra of the ﬂavin semiquinone and reduced iron–sulfur cluster,
and the distance between the ﬂavin and cluster determined by EPR.
Fig. 3. The Ubiquinone binding site of ETF-QO (Left-hand panel). View into the ubiquinone binding channel showing the position of the semi-conserved tryptophan residue at
position 443 (represented as yellow sticks). The bound ubiquinone-10 (of which only the ﬁrst ﬁve isoprene units are modelled) is shown as a ball and stick representation. The
surrounding protein shown in red except for the two hydrophobic stretches (Phe114–Leu131 and Gly427–Trp451) that line the ubiquinone binding pocket (Right-hand panel).
Residues surrounding the bound ubiquinone (ball and stick). The ﬁgure was prepared using PyMol v0_99rc6 and the coordinates from PDB ﬁle 2GMH.
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effect on the potential of the other.
Decreasing the reduction potential of either the [4Fe–4S]+1+2
cluster or the ﬂavin in the R. sphaeroides enzyme inhibits the overallFig. 4. Sequence conservation in ETF-QO Alignment of the primary amino acid sequence o
R. sphaeroides ETF-QO, the mature Human enzyme and the sequences of four model org
A. thaliana. In the case of the eukaryotic sequences the mitochondrial targeting sequence pr
ClustalW v2 [56] and subsequent output using JalView v2.4 [57]. The sequences correspon
ubiquinone binding (cyan) and cluster binding (red).steady state rate of ubiquinone reduction by ETF (Eq. (1)), because
both redox centres participate in the overall reaction. In contrast,
decreasing the potential of the [4Fe–4S]+1+2 cluster but leaving the
ﬂavin site intact speciﬁcally inhibited the rate of disproportionationf mature (after cleavage of the signal peptide) pig liver ETF-QO with the sequence of
anisms; Mouse (Mus musculus), Zebraﬁsh (Danio rerio), Drosophila melanogaster and
edicted by TargetP 1.1 [55] was removed prior to alignment of the six sequences using
ding to the domains shown in Fig. 2A are underlined as follows FAD binding (green),
1914 N.J. Watmough, F.E. Frerman / Biochimica et Biophysica Acta 1797 (2010) 1910–1916of ETF1e- (Eq. (2)). In contrast, decreasing the potential of the ﬂavin
had no effect on the disproportionation reaction. The results of these
experiments are consistent with the X-ray structure of the porcine
enzyme which suggests that the iron–sulfur cluster which is ca 8 Ǻ
from the surface of the protein is the immediate acceptor of electrons
from ETF rather than the ﬂavin which is rather more buried and ca
14 Ǻ below the surface. Consequently it would appear that electrons
are transferred from the iron–sulfur cluster to ubiquinone via the
ﬂavin.
In thewild type R. sphaeroides ETF-QO, as is the case for the pig liver
enzyme, a single electron will rapidly equilibrate between the ﬂavin
and iron–sulfur cluster because the [4Fe–4S]+1+2 cluster (+37±
7 mV) and FADox/FAD1e- (+38±12 mV) couple are isopotential. In
the 2-electron reduced wild-type enzyme, one electron resides on the
ﬂavin and one electron resides on the [4Fe–4S]+1+2 cluster [6,14,21].
However signiﬁcantly lowering of the reduction potential of the
[4Fe–4S]+1+2 cluster to −165 mV through the double mutation
Tyr501Phe/Thr525Ala (numbering follows R. sphaeroides sequence)
results in both the 1- and 2-electron reduced forms having their
electrons exclusively on the ﬂavin [21]. The ability to generate a
form of ETF-QO in which the electrons reside exclusively on the ﬂavin
will be critical to experiments aimed at resolving the mechanism of
electron and proton transfer to the bound ubiquinone.
Since electron transfer through ETF:QO [10] is reversible it may
also be instructive to study electron transfer from quinone to ﬂavin.
The skeletal muscle of adult parasitic helminths, e.g. Ascarus suum,
contain mitochondria capable of coupling the oxidation of NADH, by
an energy conserving complex I, to the reduction of either fumarate or
2-methyl branched chain acyl CoAs [34]. These anaerobically
functioning mitochondria contain rhodoquinone [35], a modiﬁed
ubiquinone in which the methoxyl group in position 3 is replaced by
an amino group, which serves as the electron acceptor for complex I
and the electron donor to both ETF-rhodoquinone oxidoreductase
(ETF:RO) [34], a homologue of ETF:QO, and fumarate reductase [36].
Although the midpoint reduction potentials of the [4Fe–4S] cluster
and the bound FAD of ETF:RO are similar to those in themitochondrial
ETF:QO, themuch lower reduction potential (−63 mV) rhodoquinone
facilitates electron transfer from the quinone pool via ETF:RO to
reduce ETF which in turn transfers electrons to a 2-methyl branched
chain enoyl-CoA reductase. Consequently synthetic rhodoquinols,
for example decyl-rhodoquinol [37], could be a useful substrate for
studying the electron transfer to ETF:QO in vitro.
5. The consequences of ETF:QO deﬁciency
In humans the disorder of intermediary metabolism known as
glutaric aciduria type II (GAII) was ﬁrst described by Przyrembel and
colleagues who proposed that the metabolic defect was localized at
catabolism of a range of acyl-CoA compounds [38]. It was later shown
that this disease, also known as MADD (multiple acyl-CoA dehydro-
genase deﬁciency), was caused by the absence or inactivity of either
ETF or ETF:QO [38]. The inability to oxidize fatty acids prevents the
synthesis of ketone bodies, an essential alternate energy source for the
heart. In such extreme cases affected individuals, who frequently die
in early infancy, present with a severe, frequently fatal, metabolic
acidosis that is often accompanied by a stress-induced hypertrophic
cardiomyopathy and lipid accumulation in the heart, and secondary
carnitine deﬁciency [39–41].
More recently milder forms of MADD that respond to riboﬂavin
therapy have been described [42,43]. Riboﬂavin responsive MADD
(RR-MADD) manifests itself in adolescence (or later) as muscle
weakness associated with intracellular lipid deposits and is associated
with a number of different pointmutations all of which result in single
amino acid substitution in the region of the protein that forms the
interface between the FAD and ubiquinone domains [44]. The clinical
presentation of these patients is quite heterogeneous for instancesome RR-MADD patients are also deﬁcient in ubiquinone-10 and the
activities of other components of the respiratory chain are depressed
[45].
It is interesting to note that an acquired MADD like syndrome
associatedwith a fatal disorder known as “atypicalmyopathy” has been
reported inhorses. This disorderwhichaffects grazing animals thathave
been at pasture for weeks–months is characterised by a complex
organic aciduria and elevated acylcarnitines in plasma and urine [46].
Whilst this presentation might suggest a deﬁciency in ETF-QO or ETF,
the activities of both enzymes are in the normal range whilst the
activities of some theprimary acyl-CoAdehydrogenases they service are
low. This has led to the proposal that a yet to be identiﬁed toxin ingested
by the animals inhibits the primary dehydrogenases [47].
Given its pivotal role in supplying the energy requirements of
cardiac muscle and type 1 skeletal muscle ﬁbres it is hard to envisage
how it is possible to study MADD in an animal model of ETF-QO
deﬁciency simply by ablating the gene. However, in plants which use
peroxisomes to β-oxidize fatty acids such an experiment is tractable.
Ishizaki et al. [48] have reported that mutating ETF-QO in Arabidopsis
thaliana considerably impairs the ability of the plants to withstand
extended periods of darkness. This is associated with signiﬁcantly
decreased sucrose levels and the accumulation of several amino
acids and isovaleryl-CoA which is both an intermediate of leucine
catabolism and a substrate for isovaleryl-CoA dehydrogenase; one
of the enzymes that uses the ETF/ETF-QO system to reoxidize its
FAD cofactor. These authors also report accumulation of phytanoyl-
CoA, an intermediate in the chlorophyll degradation pathway,
presumably due to the inability of a mitochondrial enzyme to utilise
it as a substrate, although this remains to be tested experimentally.
6. ETF-QO as a source of ROS
There are seven different sites in the mitochondrial respiratory
chain that are known to be associated with the formation of the
reactive oxygen species superoxide [49]. These sites are distributed
between the inner- and outer-faces of the inner mitochondrial
membrane. Understanding the topology of superoxide production
by the mitochondrion is important because any superoxide anion
formed in the matrix cannot cross the inner mitochondrial membrane
and if not converted by the mitochondrial superoxide dismutase to
hydrogen peroxide can potentially damage themitochondrial genome
[50]. There is evidence that under state 4 conditions (basal
respiration) there is signiﬁcant formation of superoxide by ETF-QO
in skeletal muscle mitochondria respiring palmitoylcarnitine [51].
However a more recent study suggests that mitochondria isolated
from liver and kidney, both ketogenic tissues, may be more important
sources of ROS when respiring on palmitoyl-carnitine compared with
mitochondria isolated from peripheral tissue [52]. Some considerable
care is required in interpreting studies of ROS formation by mitochon-
dria respiring on palmitoylcarnitine as the results may be dependent
both upon the fate of the acetyl-CoA formed during β-oxidation [53]
and on the oxygen tension [54]. However what does seem to be clear
is that in the presence of the complex III inhibitor antimycin and at
low membrane potentials (when reverse electron transfer from the
ubiquinone pool to complex I is disfavoured) mitochondria respiring
on long-chain fatty acids produce signiﬁcant amounts of superoxide
in the matrix [51–53]. This is best interpreted as superoxide being
formed by the ETF/ETF-QO system which has become reduced as a
result of an inability to rapidly reoxidize the ubiquinone pool. Indeed
one explanation that has been advanced for the depressed activities
of respiratory chain components in some of the RR-MADD patients
considered above is the possibility of increased oxidative damage due
to impaired ETF-QO activity [44].
The mechanism of superoxide formation by ETF-QO remains
uncertain, but it is likely to be associated with impaired electron
transfer from the ﬂavin to the ubiquinone and high steady state
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or ubiquinone. Future experiments aimed at understanding the
mechanism of electron transfer from the ﬂavin to the substrate
ubiquinone should take account the possibility of this process
generating superoxide and the potential consequences of mutations
at the interface of ﬂavin and ubiquinone binding domains. In this
respect the ability to recapitulate clinically relevant mutations in the
R. sphaeroides and evaluate their effect on the related processes of
electron-transfer and superoxide formation may prove very valuable
as we seek to better understand the pathology of MADD.
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